Recent News

• 06.13.2025 - Exploring updates in adaptive trial safety monitoring
• 06.12.2025 - Preparing to Achieve with Joint Clinical Assessments
• 06.11.2025 - AI is already delivering pharma value — and not just in drug discovery
• 06.09.2025 - Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss
• 06.09.2025 - Tackling the next frontier in metabolic trials: A Q&A with ICON experts
• 06.04.2025 - William Blair 45th Annual Growth Stock Conference
• 06.04.2025 - William Blair 45th Annual Growth Stock Conference
• 06.03.2025 - Obesity therapies and the multi-indication momentum: how industry is responding
• 05.30.2025 - Hot shots: The power and potential of study tokenisation for vaccine research and post-commercialisation
• 05.27.2025 - ICON plc to Present at the William Blair 45th Annual Growth Stock Conference

Recent Filings

• 06.11.2025 - EX-99.1 EX-99.1
• 06.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.27.2025 - EX-99.1 EX-99.1
• 05.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.23.2025 - 144 Report of proposed sale of securities
• 05.23.2025 - 144 Report of proposed sale of securities
• 05.23.2025 - 144 Report of proposed sale of securities
• 05.23.2025 - 144 Report of proposed sale of securities